TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00264810

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RNS® System implantation
Description: Using standard neurosurgical techniques the surgical team implants the RNS® System, which includes the RNS® Neurostimulator and intracranial NeuroPace® Leads. Up to 4 Leads (Cortical Strips and/or Depth Leads) are placed in or near the epileptogenic focus/foci. The Neurostimulator is placed in the skull and connected to up to 2 Leads. At first the Neurostimulator is programmed to record brain activity (electrographic patterns). The neurologist or neurosurgeon reviews the recorded electrographic patterns and identifies abnormal (epileptiform, or seizure-like) activity. The Neurostimulator is then programmed to detect the abnormal activity.
Study: NCT02977572

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-Invasive Ventilation
Description: In arm description

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Continuous Positive AirwayPressure CPAP
Description: In arm description
Study: NCT00264810

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RNS® System responsive stimulation
Description: The RNS® System is programmed to provide responsive stimulation (stimulation is ON or enabled). Upon detecting electrographic patterns, previously identified by the neurologist or neurosurgeon as abnormal (epileptiform, or seizure-like) activity, the Neurostimulator provides brief pulses of electrical stimulation through the Leads to interrupt those patterns. The typical patient is treated with a cumulative total of 5 minutes of stimulation a day.
Study: NCT02660411

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Sevoflurane will be administered by inhalation for anesthesia maintenance. The concentration of inhaled sevoflurane will be adjusted to maintain the BIS value between 40 and 60. Sevoflurane inhalational concentration will be decreased towards the end of surgery. Sevoflurane inhalation will be stopped at the end of surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol will be administered by intravenous infusion for anesthesia maintenance. The infusion rate of propofol will be adjusted to maintain the BIS value between 40 and 60. Propofol infusion rate will be decreased towards the end of surgery. Propofol infusion will be stopped at the end of surgery.
Study: NCT04713839

Intervention type: OTHER
Intervention: no intervention
Description: We didn't have an intervention program, we used two questionnaires to evaluate participants.
Study: NCT03649061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept 50 MG/ML
Description: Etanercept 50mg subcutaneous (SC) weekly added for 24 weeks to COBRA-Slim scheme

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leflunomide 10 milligram (MG)
Description: Leflunomide 10mg PO daily added to the COBRA-Slim scheme
Study: NCT02696538

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Gait Assessment
Description: Balance assessment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mini-Balance Evaluation Systems Test
Description: Balance assessment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Berg Balance Scale
Description: Balance assessment
Study: NCT01892410

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cetaphil Restoraderm Skin Restoring Body Wash
Description: Diluted (10%) 0.2ml or 0.2g of Cetaphil on semi-occlusive, hypoallergenic patch applied to skin for 24 hrs 9 times on Monday, Wednesday, and Friday for 3 weeks
Study: NCT01656330

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline
Description: Single 100 cc bolus of saline administered by intravenous (IV) injection on Day 5. Interpretation by CTRL: Concentration type = Exact ; Number = 100; unit=cc; route : intravenous use use.
Study: NCT04545996

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Suboccipital Inhibition Technique
Description: Suboccipital Inhibition Technique For 2min And Conventional Treatment Hot Pack For 10 To 15 Mints And Muscle Energy Technique(Post Facilitation Stretch) 5 Reps × 1 Set Sessions: 2 TIME A WEEK FOR 4 CONSECUTIVE WEEKS
Study: NCT03781635

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bolus of intravenous ketamine
Description: low-dose ketamine (0.25mg.kg-1) is administered intraoperatively as bolus at incision (T0) and for each hour of anesthesia untel the end of surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: continuous infusion of intravenous ketamine
Description: An infusion of low-dose ketamine (0.25 mg.kg-1.h-1) is started at T0 (incision) with an infusion pump and is kept at the same rate until the end of surgery
Study: NCT04134429

Intervention type: DEVICE
Intervention: Everion
Description: The Everion® device, by Biovotion, Zurich, is a on-skin wearable device measuring health data.
Study: NCT02056041

Intervention type: PROCEDURE
Intervention: Hepatectomy
Study: NCT02429661

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer support groups

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer support groups

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer support groups
Study: NCT04545996

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cranio Cervical Flexion Exercises.
Description: Cranio cervical flexion exercises10 repetitions for 10 seconds and conventional treatment hot pack for 10 to 15 mints and muscle energy technique(post facilitation stretch) 5 reps × 1 set Sessions: 2 TIME A WEEK FOR 4 CONSECUTIVE WEEKS
Study: NCT06413251

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Boxing Training
Description: The boxing training intervention will consist of three exercise sessions per week on nonconsecutive days for six weeks. Participants will be instructed to complete 10 rounds of three minutes with a one-minute resting period interspersed. Four rounds will consist of heavy bag punching (e.g. straight, jab, hook) at 60% VO2max and three rounds at 90-95% VO2max, while the remaining 3 rounds will be focused on mitt work at 60% VO2max.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control flexibility
Description: The control group will perform three days per week 10 minutes of dynamic articular movement, five minutes of uni pedal stance, and five minutes of stretching of the upper limbs for six weeks.
Study: NCT01891448

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WebCONSORT tool
Description: Authors are directed to the WebCONSORT tool. The tool allows authors to obtain a customized CONSORT checklist and flow diagram specific to their trial design (e.g., non-inferiority trial, pragmatic trial, cluster trial) and type of intervention (e.g., pharmacological or non pharmacological). The checklist items and flow diagram should then be reported in the manuscript and the completed checklist submitted to the journal along with the revision.

Intervention type: OTHER
Group type: OTHER
Intervention: Modified WebCONSORT tool
Description: Authors are directed to a different version of the WebCONSORT tool. This tool includes the flow diagram part of the tool but not the main checklist or elements relating to CONSORT extensions.
Study: NCT01965405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: Participant will receive a prescription for Bupropion hydrochloride and will self-administer according to dosage instructions from the study psychiatrist.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: Participant will receive a prescription for Bupropion hydrochloride and will self-administer according to dosage instructions from the study psychiatrist.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: Participant will receive a prescription for Bupropion hydrochloride and will self-administer according to dosage instructions from the study psychiatrist.
Study: NCT00549042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OROS hydromorphone
Description: hydromorphone 12, 16, 24, 32, 40, 48, or 64 mg tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01965405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: Participant will receive a prescription for Bupropion hydrochloride and will self-administer according to dosage instructions from the study psychiatrist.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: Participant will receive a prescription for Bupropion hydrochloride and will self-administer according to dosage instructions from the study psychiatrist.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: Participant will receive a prescription for Bupropion hydrochloride and will self-administer according to dosage instructions from the study psychiatrist.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Counseling
Description: Participants are provided with brief counseling for smoking cessation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Counseling
Description: Participants are provided with brief counseling for smoking cessation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Counseling
Description: Participants are provided with brief counseling for smoking cessation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-magnitude prize contingency management
Description: Prize based contingency management condition in which participants have the chance to win incentives (prizes) when they provide biological test results (expired carbon monoxide and cotinine) that are negative for recent smoking.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monitored support to quit smoking
Description: Brief supportive sessions and monitoring of smoking cessation efforts.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monitored support to quit smoking
Description: Brief supportive sessions and monitoring of smoking cessation efforts.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monitored support to quit smoking
Description: Brief supportive sessions and monitoring of smoking cessation efforts.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No additional treatment
Description: No additional treatment will be given.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prize contingency management for abstinence
Description: Prize based contingency management condition in which participants have the chance to win incentives (prizes) when they provide biological test results (expired carbon monoxide and cotinine) that are negative for recent smoking.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low intensity prize contingency management
Description: Prize based contingency management condition in which participants have the chance to win incentives (prizes) when they provide biological test results (expired carbon monoxide and cotinine) that are negative for recent smoking.
Study: NCT03760536

Intervention type: BEHAVIORAL
Intervention: 16-week Exercise Rehabilitation Program for Breast Cancer Survivors
Description: Interested patients will attend a group meeting where they will be screened and consented to the study. During weeks 1 and 2 patients will complete pre-intervention baseline assessments and blood draws followed by a 16-week supervised exercise program at Get REEL and HEAL facility. Study participants will complete progressive aerobic and resistance exercise training. Post-intervention weeks 1 and 2 participants will complete assessments, questionnaires and blood draws. Participants will be followed up at 6 and 12 months post intervention with physical assessments, questionnaires and blood draws. Annual follow-up will occur at year 2,3,4 and 5 post intervention with questionnaires only.
Study: NCT03811184

Intervention type: DIAGNOSTIC_TEST
Intervention: MemScreen
Description: Neuropsychological test on smartphone or digital tablet, on self assesment.
Study: NCT04209816

Intervention type: DIAGNOSTIC_TEST
Intervention: Lipoprotein kinetics
Description: Lipoprotein kinetic apply protocol that endogenously label proteins and fatty acids with stable isotope-labeled amino acid and glycerol tracers. De novo lipogenesis is measured after ingestion of deuterated water to measure newly formed fatty acids in VLDL. Liver fat is measured with magnetic resonance spectroscopy and lipolytic enzymes with heparin test.

Intervention type: DIAGNOSTIC_TEST
Intervention: Lipoprotein kinetics
Description: Lipoprotein kinetic apply protocol that endogenously label proteins and fatty acids with stable isotope-labeled amino acid and glycerol tracers. De novo lipogenesis is measured after ingestion of deuterated water to measure newly formed fatty acids in VLDL. Liver fat is measured with magnetic resonance spectroscopy and lipolytic enzymes with heparin test.

Intervention type: DIAGNOSTIC_TEST
Intervention: Lipoprotein kinetics
Description: Lipoprotein kinetic apply protocol that endogenously label proteins and fatty acids with stable isotope-labeled amino acid and glycerol tracers. De novo lipogenesis is measured after ingestion of deuterated water to measure newly formed fatty acids in VLDL. Liver fat is measured with magnetic resonance spectroscopy and lipolytic enzymes with heparin test.

Intervention type: DIAGNOSTIC_TEST
Intervention: Lipoprotein kinetics
Description: Lipoprotein kinetic apply protocol that endogenously label proteins and fatty acids with stable isotope-labeled amino acid and glycerol tracers. De novo lipogenesis is measured after ingestion of deuterated water to measure newly formed fatty acids in VLDL. Liver fat is measured with magnetic resonance spectroscopy and lipolytic enzymes with heparin test.

Intervention type: DIAGNOSTIC_TEST
Intervention: Lipoprotein kinetics
Description: Lipoprotein kinetic apply protocol that endogenously label proteins and fatty acids with stable isotope-labeled amino acid and glycerol tracers. De novo lipogenesis is measured after ingestion of deuterated water to measure newly formed fatty acids in VLDL. Liver fat is measured with magnetic resonance spectroscopy and lipolytic enzymes with heparin test.

Intervention type: DIAGNOSTIC_TEST
Intervention: Lipoprotein kinetics
Description: Lipoprotein kinetic apply protocol that endogenously label proteins and fatty acids with stable isotope-labeled amino acid and glycerol tracers. De novo lipogenesis is measured after ingestion of deuterated water to measure newly formed fatty acids in VLDL. Liver fat is measured with magnetic resonance spectroscopy and lipolytic enzymes with heparin test.

Intervention type: DIAGNOSTIC_TEST
Intervention: Lipoprotein kinetics
Description: Lipoprotein kinetic apply protocol that endogenously label proteins and fatty acids with stable isotope-labeled amino acid and glycerol tracers. De novo lipogenesis is measured after ingestion of deuterated water to measure newly formed fatty acids in VLDL. Liver fat is measured with magnetic resonance spectroscopy and lipolytic enzymes with heparin test.
Study: NCT03389568

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: singing-based music therapy program
Description: A single 1-hour singing-based intervention is conducted with each primary caregiver of an ICU patient. The intervention is composed of three steps: 1) listening to a participant's preferred music and identifying his and her emotional states (15 minutes), (2) singing for emotional changes (30 minutes), and (3) discussing what he or she experiences during singing and identifying how they apply such experience to their personal use of music for emotional changes in his or her everyday life (15 minutes).
Study: NCT01747564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM178 (mirabegron)
Description: oral
Study: NCT01337674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-4618
Description: Once daily oral dose of MK-4618 100 mg (two 50 mg tablets) on Days 1 through 7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-4618
Description: Once daily oral dose of MK-4618 100 mg (two 50 mg tablets) on Days 1 through 7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-4618
Description: Once daily oral dose of MK-4618 100 mg (two 50 mg tablets) on Days 1 through 7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-4618
Description: Once daily oral dose of MK-4618 100 mg (two 50 mg tablets) on Days 1 through 7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for MK-4618
Description: Once daily oral dose of placebo for MK-4618 100 mg (two 50 mg tablets) on Days 1 through 7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for MK-4618
Description: Once daily oral dose of placebo for MK-4618 100 mg (two 50 mg tablets) on Days 1 through 7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for MK-4618
Description: Once daily oral dose of placebo for MK-4618 100 mg (two 50 mg tablets) on Days 1 through 7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for MK-4618
Description: Once daily oral dose of placebo for MK-4618 100 mg (two 50 mg tablets) on Days 1 through 7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol
Description: Previously prescribed daily dose of open-label metoprolol for the duration of the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol
Description: Previously prescribed daily dose of open-label metoprolol for the duration of the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: Previously prescribed daily dose of open-label amlodipine for the duration of the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: Previously prescribed daily dose of open-label amlodipine for the duration of the study
Study: NCT03662932

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early intensive mobilization
Description: Early mobilization: mobilization with the hospital staff begins already on the day of surgery, and includes mobilization in and out of bed, rise up from a chair, standing and walking.~Intensive mobilization: mobilization more than 4 times a day in the first postoperative week.
Study: NCT03646032

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SAAFE
Description: After completing the pre-game assessment, participants will be asked to play the SAAFE game for at least 30 minutes and up to 1 hour . At the conclusion of the game, participants will be provided with a post-game assessment about their perception of risk, knowledge of specific protective behaviors, and whether they plan to change behaviors.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: This group will receive dating sim game (called Choices). They will also receive pamphlets that provide information on the testing location and care if they have HIV/STI.
Study: NCT03107078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucocorticoids
Description: Intravenous Glucocorticoids (GCs)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucocorticoids
Description: Intravenous Glucocorticoids (GCs)
Study: NCT00006483

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Study: NCT01089608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Eye drops, Dosage : 1.5%~1 drop twice daily at Day 0, then 1 drop once daily from Day 1 to Day 6 in the morning, following by a period of 2 weeks without treatment. This therapeutic scheme will be repeat 2 times.
Study: NCT00664898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Escalating intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGN-40
Description: Escalating intravenous repeating dose
Study: NCT03348072

Intervention type: PROCEDURE
Intervention: Cardiac surgery
Description: Cardiac surgery

Intervention type: PROCEDURE
Intervention: Cardiac surgery
Description: Cardiac surgery
Study: NCT01048892

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Seneca Valley virus-001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Study: NCT02660723

Intervention type: OTHER
Group type: OTHER
Intervention: Healthy Volunteers
Description: A catheter will be introduced in the arm vein and 14 ml of blood will be drawn in one 4 ml dry tube, one 5 ml heparinized tube for cell count and 5 1 ml TruCulture tubes.
Study: NCT04635579

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood flow restriction
Description: Intervention restricts blood flow to the lower limb as a percentage of the limb occlusion pressure

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Blood flow restriction
Description: Intervention restricts blood flow to the lower limb as a percentage of the limb occlusion pressure
Study: NCT02685722

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UC-MSCs Gel group
Description: This study for a six-month trials,Randomized, open, and parallel comparison before and after its own,Stage test includes screening stage, stochastic screening of more than a month difficult to heal wounds 20 people.By generating a random number of principle,Observation of UC-MSCs Gel group patients efficacy, safety and tolerability of selective parameter.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gel group
Description: This study for a six-month trials,Randomized, open, and parallel comparison before and after its own,Stage test includes screening stage, stochastic screening of more than a month difficult to heal wounds 20 people.By generating a random number of principle,observed and compared Gel group patients may be no efficacy.
Study: NCT04414579

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Faster Insulin Aspart (Fiasp®)
Description: Subjects will be randomized either to use Fiasp or conventional insulin aspart in CSII. CSII settings (basal, bolus, and correction factors) will be optimized using a meal challenge for a 2-week run in period followed by a 10-week period of CSII use with the assigned insulin. After a 12-week maintenance period, each group will cross over to the other insulin (conventional insulin aspart or Fiasp) by CSII for a second 2-week optimization period followed by a 10-week treatment period.